Gene and cell therapy developers are contending with the implications of the evolving regulatory environment while trying to progress programs as quickly as possible to address unmet needs and secure first-mover advantage in competitive indications. Regulators are facilitating efforts to truncate development timelines through a series of designations that can expedite programs while also making efforts to implement standardization.

Aldevron, the leading plasmid DNA, proteins and mRNA manufacturing company, is pleased to announce the hiring of Kenneth (Ken) Bonnell as Vice President of Quality and Regulatory Affairs.